ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Senate Democrats Introduce Bill to Allow Government to Block Drug Price Rises

Reuters Staff  |  December 14, 2018

WASHINGTON (Reuters)—Four Democratic U.S. senators introduced a bill on Thursday that would allow the government to block drug price increases that it decides are unjustified. The bill sponsored by Senators Richard Blumenthal, Kamala Harris, Amy Klobuchar and Jeff Merkley, all Democrats, would allow the Department of Health and Human Services to prohibit drug price increases…

ACR Delegates Move Rheumatology Concerns Forward at AMA

From the College  |  December 10, 2018

At the AMA’s recent House of Delegates Interim Meeting, the ACR’s delegation was able to incorporate rheumatology concerns into official AMA policy, in addition to leading a major multi-specialty resolution on the CMS-proposed move to consolidate and cut evaluation and management (E/M) services. The ACR is able to make this progress because members of the…

MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease

Lara C. Pullen, PhD  |  December 10, 2018

New research has linked the risk of developing interstitial lung disease in rheumatoid arthritis patients with the promoter variant in MUC5B, which may also contribute to the development of idiopathic pulmonary fibrosis and an unsual interstitial pneumonia seen by high-resolution CT scan…

Suleman Bhana, MD, FACR, Brings a Fresh Perspective as CMC Chair

Kelly Tyrrell  |  December 5, 2018

Chairing the ACR’s Communications and Marketing Committee (CMC) can be a monumental task: The CMC is responsible for both internal and external communications to a variety of people, including rheumatology providers, patients, lawmakers, the pharmaceutical industry and others. But the CMC’s newest chair, Suleman Bhana, MD, FACR, is up for the job. The Rheumatologist recently…

Committee on Rheumatologic Care Helps Establish Principles & Position Statements

Carina Stanton  |  December 5, 2018

The ACR’s Committee on Rheumatologic Care (CORC) has been busy on many fronts, including establishing new position statements for the College, introducing new practice perspectives and engaging multiple stakeholders in actions to protect and enhance rheumatology practice, such as with payers. “CORC ensures the rheumatology voice is heard in all of the most critical venues,”…

Swamy Venuturupalli, MD: Improving Access to Education

Carina Stanton  |  December 5, 2018

Early in his medical career, Swamy Venuturupalli, MD, sought clinical direction toward a specialty that allowed him to look at the patient in multiple domains, and he found a perfect fit in rheumatology. His passion for understanding the many aspects of rheumatic disease led Dr. Venuturupalli to become actively involved in the Rheumatology Fellowship Program…

Low Muscle Density & Physical Function in Patients with RA

Arthritis Care & Research  |  December 4, 2018

Low muscle density due to the accumulation of intramuscular fat has been observed in RA patients and is associated with higher disease activity. New research sought to understand the relationship between muscle density, physical function and strength independent of body composition, including such factors as total and visceral adiposity. The results: Compared with healthy controls, low muscle density in RA patients was associated with low muscle mass, excess adiposity and greater disability…

Patients with Psoriatic Arthritis at Increased Risk for Type 2 Diabetes

Lara C. Pullen, PhD  |  December 3, 2018

New research shows that patients with psoriatic arthritis (PsA) have a greater risk for developing type 2 diabetes than patients with psoriasis alone or the general population. Researchers also found that PsA and psoriasis patients have a similar rate of increased risk for cardiovascular disease…

Managing Multiple Rheumatic Diseases: How One Patient Copes with Her Disabilities & Advocates for Others

Karen Appold  |  November 28, 2018

By the time Kelly Conway was diagnosed with rheumatoid arthritis (RA) in 2007, she had already been living with symptoms of the disease for 23 years. Her first symptom appeared when she was 14—knee pain that was incorrectly diagnosed as tendonitis. Over the years, she has experienced fevers and sore joints. She was diagnosed with…

Silent Cardiac Impairment in SLE

Arthritis & Rheumatology  |  November 27, 2018

Drug-naive, new-onset SLE patients, even those with inactive disease, are likely to have silent cardiac impairment, according to a new study by Guo et al. Cardiac involvement is the leading cause of death in patients with lupus, and the estimates of cardiac impairment in SLE range from 31–70%. Cardiac impairment can remain unrecognized until after autopsy. These researchers investigated the use of cardiac MRI to explore early warning signs of silent cardiac involvement in SLE and determine treatment timing…

  • « Previous Page
  • 1
  • …
  • 147
  • 148
  • 149
  • 150
  • 151
  • …
  • 332
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences